Molecular Formula | C23H25ClN2O4S |
Molar Mass | 460.97 |
Density | 1.30±0.1 g/cm3(Predicted) |
Boling Point | 658.0±65.0 °C(Predicted) |
pKa | 13.38±0.20(Predicted) |
Storage Condition | 2-8℃ |
In vitro study | Relative to the potency of S1P, ponesimod had a 4.4-fold higher regulatory efficacy on the human recombinant receptor S1P1 and a 150-fold lower regulatory efficacy on S1P3. Thus, ponesimod is approximately 650-fold more selective for S1P1 than the natural ligand relative to S1P3. |
In vivo study | Ponesimod is a novel, potent and selective S1P1 receptor agonist. Ponesimod prevents edema formation, accumulation of inflammatory cells, and release of cytokines in the skin of delayed-type allergic mice. Ponesimod can prevent the increase of toe volume and joint inflammation in rats with adjuvant arthritis. Selective activation of S1P1 with ponesimod leads to a decrease in the number of peripheral blood lymphocytes and prevents lymphocyte-mediated tissue inflammation. ponesimod may exert its utility in animal models of autoimmunity and human autoimmune diseases through its effect on T cell and B cell blood cell numbers. Thus, ponesimod may be a new therapeutic option for the treatment of autoimmune diseases. Within one week after discontinuation of treatment, Ponesimod was eliminated and its medicinal effect was rapidly reversible. |
1mg | 5mg | 10mg | |
---|---|---|---|
1 mM | 2.169 ml | 10.847 ml | 21.693 ml |
5 mM | 0.434 ml | 2.169 ml | 4.339 ml |
10 mM | 0.217 ml | 1.085 ml | 2.169 ml |
5 mM | 0.043 ml | 0.217 ml | 0.434 ml |